| Stealth Peptides Inc. Announces Results from Renal Impairment Clinical Study - Centre Daily Times |
|
|
Centre Daily Times BOSTON — Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies, announced today the results of a Phase I renal impairment study with Bendavia™. Bendavia is a novel compound that |